Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease

Inclusion Criteria: * A diagnosis of wAMD. * Patients for whom the decision to initiate treatment with IVT aflibercept in a proactive regimen was made as routine clinical practice. * Treatment-naïve in the study eye (no prior therapy for wAMD). * Patient age ≥50 years of age. * Written informed patient consent before the start of data collection (according to the requirements of the local authorities and laws). Exclusion Criteria: * Participation in an investigational program with interventions outside of routine clinical practice. * Patients with contraindications to IVT aflibercept listed in the local marketing authorization. * Planned treatment regimen outside of the local marketing authorization. * Patients with eye diseases, e.g. advanced glaucoma or visually significant cataracts, likely to require surgery during the observation period in the study eye. * Concomitant ocular or systemic administration of drugs up to 3 months before IVT aflibercept treatment that could interfere with or potentiate the mechanism of action of IVT aflibercept, including other anti-VEGF agents in the fellow eye. * Any other retinal disease which may interfere with the treatment of wAMD.